Bladder cancer study aims to keep tumors at bay with immunotherapy
NCT ID NCT03171025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the immunotherapy drug nivolumab, given after standard chemo-radiation, can help prevent bladder cancer from coming back. About 200 adults with localized muscle-invasive bladder cancer who cannot have bladder removal surgery are taking part. The main goal is to see how many people are still cancer-free two years after starting treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Can a special PET scan see bladder cancer more clearly?
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?